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Purpose/Objective: Following up on the work presented at ESTRO29 
on radiobiological optimization of prostate cancer dose-painting 
radiotherapy, we now report preliminary results on the use of this 
planning approach on 17 prostate cancer patients with fMRI-, PET- 
and/or histopathologically confirmed dominant intraprostatic 
lesion(s). The treatment of this small cohort of patient is a prelude to 
the HEXPROP 3-arm trial:  
- Arm 1 : 60 Gy in 20 fractions to the prostate PTV 
- Arm 2 : 60 Gy in 20 fractions to the prostate PTV + concurrent boost 
to the DIL PTV up to 68 Gy 
- Arm 3 : 37.5 Gy in 15 fractions to the prostate PTV + 15-20 Gy HDR 
brachytherapy boost 
A modelling study of Arm 3 is also presented here.  
Materials and Methods: The patients were treated with either 60 Gy 
in 20 or 74 Gy in 37 fractions regimens to the prostate PTV. Rectal 
inverse optimization objectives were set so as to keep toxicity as 
estimated by the LKB model to the same level as for our 'standard of 
care' plans. 'Standard of care' dose-volume objectives were used for 
the other organs at risk. The DIL PTV boost level was determined by a 
TCP maximization technique. Intensity modulated rotational delivery 
was employed for all patients.  
The modelling of the combined EBRT + HDR brachytherapy treatments 
assumes a uniform dose is delivered to the prostate PTV. No 
correction for sublethal lesion repair during delivery is necessary due 
to the short duration of the HDR phase. Converting the DVHs of both 
modalities to BED using the LQ model allows us to simply add the 
doses.  
Results: Patients treated in 37 (12) and 20 (5) fractions received 
respectively an average boost of 83.1Gy (range 79-87.4Gy) and 69.2Gy 
(range 66.7-70.3Gy). The median follow-up for the treated patients is 
13 months (range 7-26 months). Treatment plans could be designed 
and the treatment completed for all patients. Observed early 
complications were grade II or less GU events for 4 patients and one 
case of grade II GI event. Regarding relatively early 'late' toxicity, one 
grade II GU and one grade I GI toxicity events have been reported so 
far.  
The modelling suggests that arm 3 should yield the best therapeutic 
ratio with low toxicity and control rates similar to arm 2.  
Conclusions: The BIOPROP trial has allowed us to gain experience and 
confidence in the dose-painting approach. Toxicity was not 
significantly different from our 'standard of care' treatments, 
consistent with our initial modelling studies. HEXPROP should offer 
patients even better outcomes. 
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Purpose/Objective: Compare intra-patient setup errors using 2 
different stereoscopic kV imaging systems,namely Varian OBI marker 
match and ExacTrac for patients with fiducial markers(FMs) for 
prostate radiotherapy.  
Material/methods:  23 patients undergoing prostate +/- seminal 
vesicles radiotherapy with ≥3 FMs were randomised to start treatment 
on one of 2 linac systems, and then to alternate weekly between 
them. Patients underwent daily imaging at setup, post correction and 
post-treatment with Varian’s marker match (v1.4 & 1.5) (linac A) 
orExacTrac (v5.5) (linac B). Matching and setup correction is in 4 dof 
(degrees of freedom) for linac A and 6 dof for linac B, i.e. a tilting 
couch top correction with linac B. Post correction, patients proceeded 
to treatment if they were within a tolerance of 3mm in each 
direction, if not further imaging and correction was applied. 
Patient population setup accuracy after initial setup to tattoos and 
post correction is compared for the different imaging systems. 
Post-treatment results, and differences in matching in 4/6dof will not 
be considered here. 
Data is available from 19 patients to date. Pre-and post-correction 
data is available from 322 fractions on linac A(7-21 fractions/patient) 
and 332 fractions on linac B (8-21 fractions/patient). 
Per patient and population setup errors are calculated for comparison 
between imaging modalities, and imaging isocentre accuracy 
compared. 
Results: Table1 shows per-patient and population systematic errors 
for ExacTrac and OBI, forboth pre- and post-correction match results.  
  
Analysis of quality assurance results show the coincidence with 
mechanical linac isocentre for ExacTrac to have a magnitude of 
0.5mm (SD 0.2mm), when broken down into each translational 
direction this corresponds to an average of 0.2mm (SD 0.2mm). For 
OBI marker match, results are 0.9mm (SD 0.4mm) and 0.4mm 
(SD0.4mm) respectively. 
The results of all 23 patients will be analysed for differences in 
individual patient post-correction systematic errors between the 2 
systems using a paired t-test. Similar methods will be used for random 
error analysis. 
Conclusion: Both imaging systems give similar population systematic 
errors at initial setup.ExacTrac has a more accurate isocentre per se, 
but the effect of correcting in 6dof compared to 4dof with OBI may 
induce a patient reaction that could affect the post-correction setup 
accuracy. 
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Purpose/Objective: To report late toxicity and 5 year biochemical 
relapse-free survival(bRFS) of the first 99 prostate cancer(PCa) 
patients treated within a Phase I-II study with moderately 
hypofractionated image-guided helical tomotherapy(HTT). 
Materials and Methods:  From 01/2006- 07/2009 99 PCa pts with 
median age of 73 yrs (56-89 yrs) underwent moderately 
hypofractionated HTT. According to NCCN staging, 45 were low 
risk(LR), 45 interemediate risk(IR), and 9 high risk(HR) pts. Low risk 
pts were treated with 71.4 Gy/28 fr on the prostate gland+ seminal 
vesicles, while intermediate and high risk pts were treated with 51.8 
Gy/ 28 fr on the pelvic lymph nodes and SIB to 74.2 Gy on the prostate 
gland. The median follow up was 5.2 yrs for the LR group, 4.9 yrs for 
the IR group and 5.6 yrs for the HR group. Neoadjuvant and/or 
concomitant and/or adjuvant deprivation therapy(ADT) was 
prescribed in 69 pts(25 LR, 37 IR, 7 HR pts). Late toxicities were 
evaluated based on RTOG/EORTC scale. Biochemical relapses were 
defined according to the ASTRO definition. 
Results: Three pts in the LR group died for other causes, 42 (100%) 
evaluable pts were in CR at the last follow up. Two pts in the IR group 
died, one with PD, the other one for other causes, and three pts were 
lost to follow up. Thirty-nine of 40 evaluable IR group pts (97.5%) 
were in CR at the last follow up, and 1 patient in biochemical relapse. 
One patient from the HR group died for a Hepatocellular carcinoma, 
6/8 (75%) were in CR and 2/8 (25%) in PD. In five yrs of f-up, 2 LR pts 
developed G3 GU late toxicity, both resolved with 
catheterization/dilatation, and now G0, and 3 pts G3 late GI toxicity, 
2 resolved with argon laser therapy(and now G0), one improved 
without therapy. Two of 40 pts in the IR group presented G3 GU 
toxicity, both improved, and 2/40 pts G3 GI toxicity, both resolved 
with argon laser therapy. No G3 toxicity was registered in the HR 
